Benoit Peyronnet1, Alexia Even2, Grégoire Capon3, Marianne De Seze4, Juliette Hascoet5, Xavier Biardeau6, Maximilien Baron7, Marie-Aimée Perrouin-Verbe8, Jean-Michel Boutin9, Christian Saussine10, Véronique Phé11, Loic Lenormand8, Emmanuel Chartier-Kastler11, Jean-Nicolas Cornu7, Gilles Karsenty12, Andrea Manunta5, Brigitte Schurch13, Pierre Denys2, Gérard Amarenco14, Xavier Game15. 1. Department of Urology, University of Rennes and French Referral Network of Spina Bifida, Rennes University Hospital, Rennes, France. Electronic address: peyronnetbenoit@hotmail.fr. 2. Department of Physical Medicine and Rehabilitation, Raymond Poincaré Hospital, Garches, France. 3. Department of Urology, University of Bordeaux, Bordeaux, France. 4. Department of NeuroUrology, Clinique Saint-Augustin, Bordeaux, France. 5. Department of Urology, University of Rennes and French Referral Network of Spina Bifida, Rennes University Hospital, Rennes, France. 6. Department of Urology, University of Lille, Lille, France. 7. Department of Urology, University of Rouen, Rouen, France. 8. Department of Urology, University of Nantes, Nantes, France. 9. Department of Urology, University of Tours, Tours, France. 10. Department of Urology, University of Strasbourg, Strasbourg, France. 11. Department of Urology, Médecine Sorbonne Universite, Paris, France. 12. Department of Urology, University of Marseille, Marseille, France. 13. Department of NeuroUrology, University of Lausanne, Lausanne, Switzerland. 14. Sorbonne Université, GRC 01 GREEN, Assistance publique-hôpitaux de Paris, Hôpital Tenon, Paris, France. 15. Department of Urology, University of Toulouse, Toulouse, France.
Abstract
PURPOSE: The aim of the current study was to determine the outcomes of botulinum toxin A intradetrusor injections in adult patients with spina bifida. MATERIALS AND METHODS: All patients with spinal dysraphism who underwent intradetrusor injections of botulinum toxin A from 2002 to 2016 at a total of 14 centers were retrospectively included in analysis. The primary end point was the global success of injections, defined subjectively as the combination of urgency, urinary incontinence and detrusor overactivity/low bladder compliance resolution. Univariate and multivariate analysis was performed to seek predictors of global success. RESULTS: A total of 125 patients were included in study. The global success rate of the first injection was 62.3% with resolution of urinary incontinence in 73.5% of patients. All urodynamic parameters had improved significantly by 6 to 8 weeks compared to baseline, including maximum detrusor pressure (-12 cm H2O, p <0.001), maximum cystometric capacity (86.6 ml, p <0.001) and compliance (8.9 ml/cm H2O, p = 0.002). A total of 20 complications (3.6%) were recorded for the 561 intradetrusor botulinum toxin A injections, including 3 muscular weakness complications. The global success rate of the first injection was significantly lower in patients with poor compliance (34.4% vs 86.9%, OR 0.08, p <0.001). On multivariate analysis poor compliance was associated with a lower global success rate (OR 0.13, p <0.001). Female gender (OR 3.53, p = 0.01) and patient age (OR 39.9, p <0.001) were predictors of global success. CONCLUSIONS: Intradetrusor botulinum toxin A injections were effective in adult patients with spina bifida who had detrusor overactivity. In contrast, effectiveness was much lower in adult patients with spina bifida who had poor bladder compliance. The other predictors of global success were female gender and older age.
PURPOSE: The aim of the current study was to determine the outcomes of botulinum toxin A intradetrusor injections in adult patients with spina bifida. MATERIALS AND METHODS: All patients with spinal dysraphism who underwent intradetrusor injections of botulinum toxin A from 2002 to 2016 at a total of 14 centers were retrospectively included in analysis. The primary end point was the global success of injections, defined subjectively as the combination of urgency, urinary incontinence and detrusor overactivity/low bladder compliance resolution. Univariate and multivariate analysis was performed to seek predictors of global success. RESULTS: A total of 125 patients were included in study. The global success rate of the first injection was 62.3% with resolution of urinary incontinence in 73.5% of patients. All urodynamic parameters had improved significantly by 6 to 8 weeks compared to baseline, including maximum detrusor pressure (-12 cm H2O, p <0.001), maximum cystometric capacity (86.6 ml, p <0.001) and compliance (8.9 ml/cm H2O, p = 0.002). A total of 20 complications (3.6%) were recorded for the 561 intradetrusor botulinum toxin A injections, including 3 muscular weakness complications. The global success rate of the first injection was significantly lower in patients with poor compliance (34.4% vs 86.9%, OR 0.08, p <0.001). On multivariate analysis poor compliance was associated with a lower global success rate (OR 0.13, p <0.001). Female gender (OR 3.53, p = 0.01) and patient age (OR 39.9, p <0.001) were predictors of global success. CONCLUSIONS: Intradetrusor botulinum toxin A injections were effective in adult patients with spina bifida who had detrusor overactivity. In contrast, effectiveness was much lower in adult patients with spina bifida who had poor bladder compliance. The other predictors of global success were female gender and older age.